Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?

Paolo Carlini(National Cancer Institute), Francesco Cognetti(Apple (Israel)), Enzo Maria Ruggeri, Riccardo Tonachella, Adriana Romiti(Sapienza University of Rome), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Federica Tomao(Sapienza University of Rome), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Papaldo(Cancer Institute (WIA)), Alessandra Fabi(Agostino Gemelli University Polyclinic)
The Journal of Steroid Biochemistry and Molecular Biology
July 1, 2003
10.1016/s0960-0760(03)00249-8
Cited by 11

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253